Skip to main content
Top
Published in: BMC Psychiatry 1/2007

Open Access 01-12-2007 | Research article

Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study

Authors: Manit Srisurapanont, Surinporn Likhitsathian, Vudhichai Boonyanaruthee, Chawanun Charnsilp, Ngamwong Jarusuraisin

Published in: BMC Psychiatry | Issue 1/2007

Login to get access

Abstract

Background

Not only the prevalence, but also the progress of metabolic abnormalities in schizophrenic patients is of importance for treatment planning and policy making. However, there have been very few prospective studies of metabolic disturbance in schizophrenic patients. This study aimed to assess the progress of metabolic abnormalities in Thai individuals with schizophrenia by estimating their one-year incidence rate of metabolic syndrome (MetS).

Methods

We screened all schizophrenic patients who visited our psychiatric clinic. After the exclusion of participants with MetS at baseline, each subject was reassessed at 6 and 12 months to determine the occurrence of MetS. The definition of MetS, as proposed by the International Diabetes Federation (IDF), was applied.

Results

Fifty-seven participants (24 males and 33 females) had a mean of age and duration of antipsychotic treatment of 37.5 years old and 8.4 years, respectively. At baseline, 13 subjects met the MetS definition. Of 44 subjects who had no MetS at baseline, 35 could be followed up. Seven of these 35 subjects (20.0%) had developed MetS at the 6- or 12-month visit, after already having 2 MetS components at baseline. The demographic data and characteristics of those developing and not developing MetS were not different in any respect.

Conclusion

Thai schizophrenic patients are likely to develop MetS. Their metabolic abnormalities may progress rapidly and fulfill the MetS definition within a year of follow-up. These findings support the importance of assessing and monitoring metabolic syndrome in schizophrenic patients.
Literature
1.
go back to reference Galassi A, Reynolds K, He J: Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med. 2006, 119: 812-9. 10.1016/j.amjmed.2006.02.031.CrossRefPubMed Galassi A, Reynolds K, He J: Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med. 2006, 119: 812-9. 10.1016/j.amjmed.2006.02.031.CrossRefPubMed
2.
go back to reference Expert Panel on Detection and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001, 285: 2486-2497. 10.1001/jama.285.19.2486.CrossRef Expert Panel on Detection and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001, 285: 2486-2497. 10.1001/jama.285.19.2486.CrossRef
3.
go back to reference Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Costa F: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement (executive summary). Circulation. 2005, 112: 2735-2752. 10.1161/CIRCULATIONAHA.105.169404.CrossRefPubMed Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, Costa F: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement (executive summary). Circulation. 2005, 112: 2735-2752. 10.1161/CIRCULATIONAHA.105.169404.CrossRefPubMed
4.
go back to reference Alberti KGMM, Zimmet P, Shaw J: Metabolic syndrome – a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2005, 23: 469-480. 10.1111/j.1464-5491.2006.01858.x.CrossRef Alberti KGMM, Zimmet P, Shaw J: Metabolic syndrome – a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2005, 23: 469-480. 10.1111/j.1464-5491.2006.01858.x.CrossRef
5.
go back to reference Cohn T, Prud'homme D, Streiner D, Kameh H, Remington G: Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry. 2004, 49: 753-760.PubMed Cohn T, Prud'homme D, Streiner D, Kameh H, Remington G: Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry. 2004, 49: 753-760.PubMed
6.
go back to reference McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Stroup TC, Lieberman JA: Prevalence of metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005, 80: 19-32. 10.1016/j.schres.2005.07.014.CrossRefPubMed McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Stroup TC, Lieberman JA: Prevalence of metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005, 80: 19-32. 10.1016/j.schres.2005.07.014.CrossRefPubMed
7.
go back to reference De Hert MA, van Eyck D, Hanssens L, van Winkel R, Wampers M, Scheen A, Peuskens J: Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophre Res. 2006, 83: 87-93. 10.1016/j.schres.2005.12.855.CrossRef De Hert MA, van Eyck D, Hanssens L, van Winkel R, Wampers M, Scheen A, Peuskens J: Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophre Res. 2006, 83: 87-93. 10.1016/j.schres.2005.12.855.CrossRef
8.
go back to reference Saari KM, Lindeman SM, Viilo KM, Isohanni MK, Jarveline MR, Lauren LH, Savolainen MJ, Koponen HJ: A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 birth cohort study. J Clin Psychiatry. 2005, 66: 559-563.CrossRefPubMed Saari KM, Lindeman SM, Viilo KM, Isohanni MK, Jarveline MR, Lauren LH, Savolainen MJ, Koponen HJ: A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 birth cohort study. J Clin Psychiatry. 2005, 66: 559-563.CrossRefPubMed
9.
go back to reference Isomaa B, Almgen P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001, 24: 683-689. 10.2337/diacare.24.4.683.CrossRefPubMed Isomaa B, Almgen P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001, 24: 683-689. 10.2337/diacare.24.4.683.CrossRefPubMed
10.
go back to reference Osby U, Correia N, Brandt L, Ekbom A, Sparen P: Mortality and causes of death in schizophrenia in Stockholm County, Sweden. Schizophr Res. 2000, 45: 21-28. 10.1016/S0920-9964(99)00191-7.CrossRefPubMed Osby U, Correia N, Brandt L, Ekbom A, Sparen P: Mortality and causes of death in schizophrenia in Stockholm County, Sweden. Schizophr Res. 2000, 45: 21-28. 10.1016/S0920-9964(99)00191-7.CrossRefPubMed
11.
go back to reference Osborn DPJ, Levy G, Nazareth I, Petersen I, Islam A, King MB: Relative Risk of Cardiovascular and Cancer Mortality in People With Severe Mental Illness From the United Kingdom's General Practice Research Database. Arch Gen Psychiatry. 2007, 64: 242-249. 10.1001/archpsyc.64.2.242.CrossRefPubMed Osborn DPJ, Levy G, Nazareth I, Petersen I, Islam A, King MB: Relative Risk of Cardiovascular and Cancer Mortality in People With Severe Mental Illness From the United Kingdom's General Practice Research Database. Arch Gen Psychiatry. 2007, 64: 242-249. 10.1001/archpsyc.64.2.242.CrossRefPubMed
12.
go back to reference Rodgers PT, Fuke DC: New and emerging strategies for reducing cardiometabolic risk factors. Pharmacotherapy. 2006, 26 (5 Pt 2): 13S-31S. 10.1592/phco.26.5part2.13S.CrossRefPubMed Rodgers PT, Fuke DC: New and emerging strategies for reducing cardiometabolic risk factors. Pharmacotherapy. 2006, 26 (5 Pt 2): 13S-31S. 10.1592/phco.26.5part2.13S.CrossRefPubMed
13.
go back to reference Haffner SM, Ruilope L, Dahlof B, Abadie E, Kupfer S, Zannad F: Metabolic syndrome, new onset diabetes, and new end points in cardiovascular trials. J Cardiovasc Pharmacol. 2006, 47: 469-475.PubMed Haffner SM, Ruilope L, Dahlof B, Abadie E, Kupfer S, Zannad F: Metabolic syndrome, new onset diabetes, and new end points in cardiovascular trials. J Cardiovasc Pharmacol. 2006, 47: 469-475.PubMed
14.
go back to reference Balkau B, Vernay M, Mhamdi L, Novak M, Arondel D, Vol S, Tichet J, Eschwege E, the D.E.S.I.R. Study Group: The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French D.E.S.I.R. study. Diabetes Metab. 2003, 29: 526-532. 10.1016/S1262-3636(07)70067-8.CrossRefPubMed Balkau B, Vernay M, Mhamdi L, Novak M, Arondel D, Vol S, Tichet J, Eschwege E, the D.E.S.I.R. Study Group: The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French D.E.S.I.R. study. Diabetes Metab. 2003, 29: 526-532. 10.1016/S1262-3636(07)70067-8.CrossRefPubMed
15.
go back to reference Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005, 353: 1209-1223. 10.1056/NEJMoa051688.CrossRefPubMed Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005, 353: 1209-1223. 10.1056/NEJMoa051688.CrossRefPubMed
16.
go back to reference Cameron AJ, Shaw JE, Zimmet PZ: The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am. 2004, 33: 351-375. 10.1016/j.ecl.2004.03.005.CrossRefPubMed Cameron AJ, Shaw JE, Zimmet PZ: The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am. 2004, 33: 351-375. 10.1016/j.ecl.2004.03.005.CrossRefPubMed
17.
go back to reference Kato MM, Currier B, Gomez CM, Hall L, Gonzalez-Blanco M: Prevalence of metabolic syndrome in Hispanic and non-Hispanic patients with schizophrenia. Prim Care Companion J Clin Psychiatry. 2004, 6: 74-77.CrossRefPubMedPubMedCentral Kato MM, Currier B, Gomez CM, Hall L, Gonzalez-Blanco M: Prevalence of metabolic syndrome in Hispanic and non-Hispanic patients with schizophrenia. Prim Care Companion J Clin Psychiatry. 2004, 6: 74-77.CrossRefPubMedPubMedCentral
18.
go back to reference American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists and North American Association for the Study of Obesity: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004, 27: 596-601. 10.2337/diacare.27.9.2262.CrossRef American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists and North American Association for the Study of Obesity: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004, 27: 596-601. 10.2337/diacare.27.9.2262.CrossRef
19.
go back to reference Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Pi-Sunyer X, Bigger JT, Friedman A, Kleinberg D, Yevich SJ, Davis B, Shon S: Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004, 161: 1334-1349. 10.1176/appi.ajp.161.8.1334.CrossRefPubMed Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Pi-Sunyer X, Bigger JT, Friedman A, Kleinberg D, Yevich SJ, Davis B, Shon S: Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004, 161: 1334-1349. 10.1176/appi.ajp.161.8.1334.CrossRefPubMed
Metadata
Title
Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study
Authors
Manit Srisurapanont
Surinporn Likhitsathian
Vudhichai Boonyanaruthee
Chawanun Charnsilp
Ngamwong Jarusuraisin
Publication date
01-12-2007
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2007
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/1471-244X-7-14

Other articles of this Issue 1/2007

BMC Psychiatry 1/2007 Go to the issue